F610C compound heterozygous mutation may lead to a reduction in the affinity of the calpain inhibitor calpastatin for CAPN1, leading to increased calpain activity in patients and supporting the hypothesis of using calpain inhibitors as a therapeutic strategy in SMA (de la Fuente et al., 2019). This evidence concerns the gene CAST and proximal spinal muscular atrophy.